Trials / Completed
CompletedNCT03927287
Prognostic Role of Free Psa Ratio at Biochemical Recurrence After Radical Treatments for Prostate Cancer
An "Old" Biomarker That Can Learn New Tricks: Prognostic Role of Free Psa Ratio at Biochemical Recurrence After Radical Treatments for Prostate Cancer
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 822 (actual)
- Sponsor
- Rabin Medical Center · Academic / Other
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Measurement of Free PSA ratio in patients after definitive radical treatment for prostate cancer, and assessment of whether post-treatment free PSA ratio can function as a biomarker for advanced disease in prostate cancer patients.
Detailed description
Prostatic specific antigen (PSA) circulates mostly in complex with protease inhibitors, but 10-30% circulates as inactive free-PSA (FPSA). In patients with prostate cancer (PCa), pretreatment FPSA is lower and used to risk-stratify patients for biopsy. However, posttreatment FPSA ratio (FPSAR) is rarely quantified, with an unexplored clinical value. Methods The institutional database was queried to identify patients following radical prostatectomy (RP cohort) or radiotherapy (RT cohort) between 2000 and 2017. For validation, the investigators identified an independent prospective cohort with biochemical recurrence (BCR) after RP, using biobank samples (biobank cohort). All patients had at least one posttreatment FPSAR test. Kaplan-Meier (KM) method was used to compare the metastasis-free (MFS), castration-resistant PCa (CRPC)-free, and cancer-specific-survival (CSS) rates. Multivariable Cox models determined the association between posttreatment FPSAR, metastases, and CRPC.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | Free PSA ratio test in patients after definitive treatment for localized prostate cancer | Free PSA ratio blood test done on biobank samples of patients after radical prostatectomy who developed biochemical recurrence. |
Timeline
- Start date
- 2018-01-01
- Primary completion
- 2018-12-30
- Completion
- 2019-04-10
- First posted
- 2019-04-25
- Last updated
- 2019-04-25
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT03927287. Inclusion in this directory is not an endorsement.